Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has challenged healthcare systems worldwide since late 2019. The interleukin-6 inhibitor tocilizumab is one of the most studied agents with a proven benefit for patients with severe and critical coronavirus disease 2019 (COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Adre, Lorenzo Abednego B, Catangui, Josefino S, Bondoc, Marvin Keith V, Abdurahman, Kenerham M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299758/
https://www.ncbi.nlm.nih.gov/pubmed/37384095
http://dx.doi.org/10.7759/cureus.39604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299758/
https://www.ncbi.nlm.nih.gov/pubmed/37384095
http://dx.doi.org/10.7759/cureus.39604

Ejemplares similares